Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Castle Biosciences Inc
(NQ:
CSTL
)
21.34
-0.82 (-3.70%)
Streaming Delayed Price
Updated: 10:50 AM EDT, Jun 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Castle Biosciences Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Castle Biosciences Presents Data from Suite of Dermatologic Cancer Genomic Tests at Fall Clinical Dermatology Conference 2021
October 22, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Acquire Cernostics
October 19, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences President and CEO Derek Maetzold Will Deliver Keynote Presentation During Arizona Bioscience Week
September 28, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces New York Approval of DecisionDx® DiffDx™-Melanoma
September 16, 2021
From
Castle Biosciences
Via
Business Wire
Castle Biosciences Recognized as a Top 100 Healthcare Technology Company of 2021
August 30, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present at Upcoming Investor Conferences
August 26, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma
August 24, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents New Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the 2021 American Academy of Dermatology (AAD) Summer Meeting
August 16, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces Second Quarter 2021 Results
August 09, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present Data at the 2021 American Academy of Dermatology (AAD) Summer Meeting
August 06, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the DERM2021 NP/PA CME Conference
August 05, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Collaborates with the Melanoma Research Foundation
August 02, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Participate at the Canaccord Genuity 41st Annual Growth Conference
July 28, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Release Second Quarter 2021 Financial Results and Host Conference Call on Monday, Aug. 9, 2021
July 26, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck
July 23, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at SDPA Annual Summer Dermatology Conference 2021
July 22, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Expands its Board of Directors with New Appointments
July 16, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences is Listed in the Houston Chronicle’s “CHRON 100” as One of the 100 Most Successful Publicly Traded Companies in Houston
June 21, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces Receipt of New York Laboratory Permit
June 09, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Participate at the Baird 2021 Healthcare ESG Symposium
June 07, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Host Ribbon Cutting Ceremony at New Corporate Headquarters
May 24, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Supports the American Skin Association with Research Grant
May 21, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors
May 20, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Participate in the Oppenheimer MedTech, Tools, & Diagnostics Summit
May 19, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Tiffany Olson, Seasoned Diagnostics Executive, Joins Castle Biosciences’ Board of Directors
May 11, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces First Quarter 2021 Results
May 10, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic Dermatitis and Related Conditions
May 10, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Recognized for Skin Cancer Diagnostics Innovation in 2021 MedTech Breakthrough Awards Program
May 06, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test
May 05, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.
May 04, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.